February 22: Switzerland Mulls Response to Trump’s 15% Tariffs

Trump 15% tariffs are back in focus for Switzerland as Bern weighs its options. The White House plans a temporary 15% Section 122 surcharge for up to 150 days, with pharma and aircraft exemptions intact. Swiss lawmakers will debate whether to keep tariff relief on select US imports, a choice that could shape Switzerland US trade costs, pricing power, and deal-making momentum. We explain near-term risks, scenarios, and what investors should track now.

What the 15% move means now

Under Section 122, the US can impose a temporary surcharge of up to 15% for 150 days. The administration plans to set the rate at 15%, reportedly after a court ruling, while preserving exemptions for pharma and aircraft shipments. This is a border charge on customs value, affecting landed prices and margins for many goods entering the US source.

Exposure varies by product. Machinery, precision instruments, watches, specialty chemicals, and food face the 15% levy. Pharmaceutical and aircraft-related goods remain exempt, softening the blow for large life sciences and aerospace suppliers. Companies must decide whether to pass costs to US buyers or absorb them. Pricing, contract terms, and delivery timing will drive margin outcomes over the surcharge window.

Parliament’s debate in Bern

Parliament will soon debate whether tariff relief for US goods should remain in place, according to public broadcaster SRF. Keeping relief could support talks with Washington and reduce pressure on consumers and firms. Changing course risks tit-for-tat measures. The decision signals Switzerland’s stance on de-escalation and reciprocity in Switzerland US trade source.

Bern faces a clear trade-off. Maintaining relief may help negotiations, while suspension would mirror US restrictions and raise domestic costs. Any switch requires parliamentary approval and time for customs to implement, so firms should not expect overnight changes. Policymakers are likely to prioritize stability, protect key sectors, and avoid unnecessary shocks to supply chains.

Pricing, contracts, and risk management

Firms should review US contracts for surcharge pass-through, price-adjustment clauses, and delivery terms. Cost-plus or indexation helps share the 15% burden. Revisit Incoterms, land more stock ahead of deadlines if possible, and align quotes in CHF with updated USD assumptions. Investors should favor companies with pricing power, flexible contracts, diversified channels, and active currency hedging.

Exemptions for pharma and aircraft-related shipments cushion a large part of Swiss high-value exports. Higher exposure sits in watches, machinery, specialty chemicals, and selected foods. SMEs may face added paperwork and cash flow strain at customs. Larger firms can pool logistics, optimize tariff classifications, and shift product mixes to items with lower effective duty rates.

Scenarios for the next 150 days

Best case: a standstill understanding narrows coverage, and the surcharge expires on schedule. Base case: Trump 15% tariffs run the full 150 days while Bern keeps relief to preserve talks. Stress case: the US extends or broadens measures and Switzerland suspends relief, raising prices on both sides and amplifying earnings volatility.

Track US revenue share, tariff classifications, and ability to reprice quickly. Review backlog terms, inventory buffers, and delivery timing. Gauge pricing power in US distribution. Watch management guidance sensitivity to customs costs and FX. Monitor parliamentary debate, US policy notices, and sector updates for any change in exemptions or timelines.

Final Thoughts

For investors, the takeaways are practical. Trump 15% tariffs lift landed costs and test pricing power. Pharma and aircraft exemptions limit the hit for some exporters, but watches, machinery, and specialty chemicals face real pressure. Parliament’s choice on US tariff relief will signal Switzerland’s strategy and affect reciprocity risks. Over the 150-day window, focus on firms with clear pass-through rights, flexible contracts, and disciplined USD hedging. Watch for customs notices, any shift in exemptions, and the pace of talks flagged by Bern and Washington. Position for base-case continuity, but plan for stress-case volatility.

FAQs

What is the Section 122 surcharge and how long can it last?

Section 122 of US trade law permits a temporary import surcharge of up to 15% for a maximum of 150 days. It is applied at the border on the customs value of goods. The current plan sets the rate at 15%, with exemptions for pharma and aircraft shipments remaining in place for now.

Which Swiss sectors are most exposed to the Trump 15% tariffs?

Exposure is highest in watches, machinery, precision tools, specialty chemicals, and some foods. Pharmaceutical and aircraft-related shipments are exempt, which reduces the burden on major life sciences and aerospace suppliers. Companies with weak pricing power or rigid contracts face the greatest near-term margin risk in the US market.

What is Parliament debating regarding US imports?

Lawmakers will consider whether to keep tariff relief on select US imports. Keeping relief could support talks with Washington and limit domestic cost increases. Suspending relief would mirror US restrictions but may raise prices for Swiss firms and consumers. The outcome will guide policy signals and reciprocity over the coming months.

What should investors monitor during the 150-day window?

Focus on contract pass-through terms, pricing actions in the US, and guidance sensitivity to customs costs and USD moves. Track any changes to exemptions, customs implementation notices, and the timing of the parliamentary debate. Company updates on inventory, delivery timing, and product mix shifts will also be key signals.

Disclaimer:
The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.